Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jnci/djt355 | DOI Listing |
Neuropsychopharmacol Hung
December 2024
Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University, Budapest, Hungary.
Background: Major depressive disorder (MDD) is a complex psychiatric condition significantly impacted by environmental stress and inflammation. Previous research suggests that stress-induced alterations in the blood-brain barrier (BBB) may allow pro-inflammatory cytokines like interleukin-6 (IL-6) to enter the brain, contributing to depression. Tumor necrosis factor-alpha (TNF-α) is another prominent cytokine implicated in depression, but its role in the context of BBB integrity and stress-mediated depression remains unclear.
View Article and Find Full Text PDFRev Med Chil
May 2024
Departamento de Farmacología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Unlabelled: Serotonin plays a central role in mood regulation and the development of depressive disorders. The serotonin transporter, the primary regulator of serotonin levels, presents genetic variants that affect its functionality.
Aim: To study whether functional bi-allelic 5-HTTLPR or tri-allelic 5-HTTLPR/rs25531 polymorphisms in the serotonin transporter gene are associated with the diagnosis of depression.
Am J Hum Biol
January 2025
Department of Anthropology, The Pennsylvania State University, University Park, Pennsylvania, USA.
Objectives: The Developmental Origins of Health and Disease (DOHaD) framework contends that chronic diseases are attributable to behavioral and environmental risks encountered during vital periods of fetal and childhood development. Clinical research investigating irritable bowel syndrome (IBS) largely focuses on adult risk factors, with emerging evidence of epigenetic contributions. Limited work considers potential childhood exposures.
View Article and Find Full Text PDFComput Struct Biotechnol J
December 2024
Cell Culture and Fermentation Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge UK.
The secretory capacity of Chinese hamster ovary (CHO) cells remains a fundamental bottleneck in the manufacturing of protein-based therapeutics. Unconventional biological drugs with complex structures and processing requirements are particularly problematic. Although engineered vector DNA elements can achieve rapid and high-level therapeutic protein production, a high metabolic and protein folding burden is imposed on the host cell.
View Article and Find Full Text PDFTher Adv Med Oncol
January 2025
Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, China.
Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations.
Objectives: This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!